One salient example is the identification of the synthetic lethal gene pair, BRCA and PARP, which led to the development of PARP inhibitor therapies, e.g., niraparib, for patients with ovarian or breast cancers with BRCA mutations (Hartwell et al., 1997). This evidence concerns the gene PARP1 and breast carcinoma.